4MO Development and validation of CDKPredX, a novel predictor of response to neoadjuvant endocrine therapy and CDK4/6 inhibitors versus chemotherapy in ER+/HER2- breast cancer: Correlative analysis of the randomized phase II PREDIX luminal B trial

The use of CDK4/6 inhibitors (CDK4/6i) in the neoadjuvant therapy of ER+/HER2- breast cancer is under investigation. This study aimed to identify predictive biomarkers for response to CDK4/6i + endocrine therapy (ET) versus chemotherapy in clinically high-risk, early luminal breast cancer.